OBJECTIVE: To investigate the efficacy of brachytherapy for @entity1 with @entity263 and the influence factors. METHODS: There were 61 @entity1 with @entity263 were treated with brachytherapy between April 2001 and March 2011 in Department of Urology, Peking University First Hospital, including 11 @entity1 who received combined external beam radiotherapy. The mean age was 75.2 years (range 57-84 years). Clinical stage was T1c in 12 @entity1 , T2a in 18 @entity1 , T2b in 17 @entity1 , and T2c in 14 @entity1 . Long-term follow-up was carried on all @entity1 for @entity1486 (PSA) and adverse effects. Kaplan-Meier survival curves, Log-rank test and univariate Cox proportional hazard regression analysis was used to examine the factors associated with the treatment efficacy. RESULTS: The median follow-up was 49 months (range 9-126 months). The mean PSA before treatment and the mean nadir PSA after operation were (17.80    14.44)   g/L and (1.16    1.15)   g/L, respectively. The PSA of 58 @entity1 (95.1%) reached a nadir < 4.0   g/L, which was even < 1.0   g/L in 37 @entity1 (60.7%). The mean time to reach the nadir PSA was 11.6 months after operation. The short-term adverse events after operation included fever in 4 @entity1 , @entity811 in 7 @entity1 , and @entity360 in 4 @entity1 . The most common long-term adverse event was urinary irritation (31.1%); other long-term adverse events were rare, including @entity360 , @entity811 , @entity322 , @entity6112 , mild @entity294 and @entity1161 . The estimated mean biochemical recurrence-free survival after brachytherapy was 41.0 months (95% CI: 31.05-50.94 months). The mean nadir PSA after operation were 1.32   g/L in the 11 @entity1 who received combined external beam radiotherapy, and their estimated mean biochemical recurrence-free survival was 38 months. @entity1 with nadir PSA < 1.0   g/L had a significant longer biochemical recurrence-free survival than those with nadir PSA between 1.0   g/L and 4.0   g/L (42.9 vs. 32.0 months,   (2) = 4.445, P = 0.035). CONCLUSIONS: Brachytherapy is an effective treatment strategy for @entity263 , with relatively low rate of severe adverse events. After brachytherapy, a nadir PSA < 1.0   g/L might indicate a better prognosis.

[Research of efficacy of brachytherapy for XXXX ].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer'] @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence'] @entity6112 :: ('MESH:D016055', 'Disease') :: ['urinary retention'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation enteritis'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria'] @entity360 :: ('MESH:D006471', 'Disease') :: ['hematochezia'] @entity1486 :: ('354', 'Gene') :: ['prostate specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
